246 results on '"Saijo, N."'
Search Results
2. Analysis of predictive factors in non-small cell lung cancer patients treated with nivolumab
3. Nivolumab treatment beyond progression disease in advanced non-small cell lung cancer
4. P2.01-60 Analysis of Prognostic Factors According to Performance Status in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
5. P3.01-87 Efficacy and Safety of Pembrolizumab in Non-Small Cell Lung Cancer in Our Institution: A Retrospective Study
6. P3.01-97 Which is Better Prognostic Factor, PS, Inflammatory Marker, or PD-L1 Expression in Treating NSCLC with Nivolmab; A Retrospective Analysis
7. P3.01-99 Effect of Pembrolizumab on Patients Harboring Uncommon Epidermal Growth Factor Receptor Mutations
8. Evaluating NSCLC Treatment Options Using Real World Data: Findings from an Oncology Survey Across Eight Countries
9. The efficacy of dose reduced crizotinib for advanced ALK-positive non-small cell lung cancer
10. Nab-paclitaxel in combination with carboplatin versus docetaxel in chemotherapy-naïve with advanced non-small-cell lung cancer aged 75 years old or more: Retrospective cohort study
11. The efficacy of a reduced dose (40mg) of osimertinib with T790M-positive advanced non-small-cell lung cancer
12. Final analysis of phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations
13. PL 04.02 Where We Are Now, and Where We Will Be in 10 years: From Asian Perspective
14. 426PD Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC
15. Effect of Combined Chemotherapy with Lysosome Labilizers and Mitomycin-C
16. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
17. HSP70 Causes EGFR-Tkis Resistance in a Mutant EGFR Expressed Non-Small-Cell Lung Cancer
18. Standard Thoracic Radiotherapy with or without Concurrent Daily Low-Dose Carboplatin in Elderly Patients with Locally Advanced Non-Small Cell Lung Cancer: A Phase III Trial of the Japan Clinical Oncology Group (JCOG0301)
19. A Phase III Study Comparing Amrubicin and Cisplatin (AP) with Irinotecan and Cisplatin (IP) for the Treatment of Extended-Stage Small Cell Lung Cancer (ED-SCLC): JCOG0509
20. Randomized Phase III Study Comparing Etoposide and Cisplatin (EP) with Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Radiotherapy (EP/AHTRT) for the Treatment of Limited-Stage Small-Cell Lung Cancer (LD-SCLC): JCOG0202
21. Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402)
22. Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation
23. Preface for JCOG Review Series
24. 9132 POSTER Efficacy Outcomes in First-line Treatment of Advanced NSCLC With Gefitinib (G) vs Carboplatin/paclitaxel (C/P) by Epidermal Growth Factor Receptor (EGFR) Gene-copy Number Score and by Most Common EGFR Mutation Subtypes – Exploratory Data From IPASS
25. 4001 ORAL Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients With Locally Advanced Non-small Cell Lung Cancer – a Phase III Trial of the Japan Clinical Oncology Group (JCOG0301)
26. 9134 POSTER Tumour Response, Skin Rash and Health-related Quality of Life (HRQoL) – Post-hoc Data From the IPASS Study
27. 3066 POSTER Erythropoiesis-stimulating Agents for the Treatment of Chemotherapy-induced Anemia and Mortality: a Meta-analysis of Individual Patient Data From Japanese Randomized Trials
28. Effect of cytidine deaminase (CDA)–related biomarkers on overall survival in patients with advanced pancreatic cancer receiving gemcitabine (GEM) monotherapy.
29. An analysis of serum heparan sulfate concentration and EGFR tyrosine kinase inhibitor treatment in patients with non-small cell lung adenocarcinoma.
30. Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): An intergroup trial of JCOG0803/WJOG4307L.
31. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo
32. Lung Cancer Working Group Report
33. A Phase II Study of Cisplatin and Irinotecan As Induction Chemotherapy Followed by Concomitant Thoracic Radiotherapy with Weekly Low-dose Irinotecan in Unresectable, Stage III, Non-Small Cell Lung Cancer: JCOG 9706
34. Progress in Cancer Chemotherapy with Special Stress on Molecular-targeted Therapy
35. Randomized Phase 2 Dose-finding Study of Weekly Administration of Darbepoetin Alfa in Anemic Patients with Lung or Ovarian Cancer Receiving Multicycle Platinum-containing Chemotherapy
36. Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC).
37. A phase II trial of zoledronic acid in combination with cisplatin and docetaxel in non-small cell lung cancer patients with bone metastases.
38. Safety and efficacy trial of cisplatin (P) with vinorelbine (V) followed by gefitinib (G) and concurrent thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): Japan Clinical Oncology Group (JCOG) 0402.
39. Heregulin as a novel cetuximab-resistace factor in colorectal cancer.
40. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
41. OP78 EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC)
42. A Phase II Study of Cisplatin and Irinotecan as Induction Chemotherapy Followed by Accelerated Hyperfractionated Thoracic Radiotherapy with Daily Low-dose Carboplatin in Unresectable Stage III Non-small Cell Lung Cancer: JCOG 9510
43. 9008 Clinical outcomes of bevacizumab in combination with paclitaxel/carboplatin compared with paclitaxel/carboplatin alone in previously untreated Japanese patients with advanced non-squamous non-small-cell lung cancer (NSCLC)
44. 9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
45. 9069 A risk–benefit analysis according to age using pooled data from two phase II trials of cisplatin plus S-1 for non-small-cell lung cancer in Japan
46. Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel
47. Reply to ‘Malignant pericardial effusion: sclerotherapy or local chemotherapy?’
48. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
49. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
50. A Phase I Study of Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.